{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T03:10:06Z","timestamp":1745896206891,"version":"3.40.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Research and Development Program of Shaanxi Province","award":["2018ZDXM-SF-039"],"award-info":[{"award-number":["2018ZDXM-SF-039"]}]},{"name":"the Key Industry Innovation Chain Program of Shaanxi Province","award":["2020ZDLSF02-01"],"award-info":[{"award-number":["2020ZDLSF02-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02448-9","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T02:35:24Z","timestamp":1745894124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Ruijun","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanggang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gongzhizi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"5","key":"2448_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjh.17172","volume":"192","author":"K Adelborg","year":"2021","unstructured":"Adelborg K, Larsen JB, Hvas AM. Disseminated intravascular coagulation: epidemiology, biomarkers, and management. Br J Haematol. 2021;192(5):803\u201318. https:\/\/doi.org\/10.1111\/bjh.17172.","journal-title":"Br J Haematol"},{"key":"2448_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12959-016-0117-x","volume":"14","author":"H Asakura","year":"2016","unstructured":"Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on thrombosis and hemostasis. Thromb J. 2016;14:42. https:\/\/doi.org\/10.1186\/s12959-016-0117-x.","journal-title":"Thromb J"},{"issue":"10297","key":"2448_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8.","journal-title":"Lancet"},{"issue":"1","key":"2448_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","volume":"6","author":"MM Boyiadzis","year":"2018","unstructured":"Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6(1):137. https:\/\/doi.org\/10.1186\/s40425-018-0460-5.","journal-title":"J Immunother Cancer"},{"issue":"26","key":"2448_CR5","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751.","journal-title":"Blood"},{"key":"2448_CR6","doi-asserted-by":"publisher","unstructured":"Dong R, Wang Y, Lin Y, Sun X, Xing C, Zhang Y, et al. The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study. Ann Transl Med. 2022;10(18):975. https:\/\/doi.org\/10.21037\/atm-22-3814.","DOI":"10.21037\/atm-22-3814"},{"issue":"12","key":"2448_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fern\u00e1ndez de Larrea","year":"2021","unstructured":"Fern\u00e1ndez de Larrea C, Kyle R, Rosi\u00f1ol L, Paiva B, Engelhardt M, Usmani S, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192. https:\/\/doi.org\/10.1038\/s41408-021-00587-0.","journal-title":"Blood Cancer J"},{"key":"2448_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02129-y","author":"L Fischer","year":"2024","unstructured":"Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, et al. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-023-02129-y.","journal-title":"Leukemia"},{"issue":"11","key":"2448_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-018-0135-y","volume":"8","author":"D Fotiou","year":"2018","unstructured":"Fotiou D, Sergentanis TN, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, et al. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018;8(11):102. https:\/\/doi.org\/10.1038\/s41408-018-0135-y.","journal-title":"Blood Cancer J"},{"issue":"4","key":"2448_CR10","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2448_CR11","doi-asserted-by":"publisher","first-page":"6689457","DOI":"10.1155\/2021\/6689457","volume":"2021","author":"C Geng","year":"2021","unstructured":"Geng C, Yang G, Wang H, Zhang Z, Zhou H, Chen W. The prognostic role of prothrombin time and activated partial thromboplastin time in patients with newly diagnosed multiple myeloma. Biomed Res Int. 2021;2021:6689457. https:\/\/doi.org\/10.1155\/2021\/6689457.","journal-title":"Biomed Res Int"},{"issue":"12","key":"2448_CR12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0698.","journal-title":"Cancer Discov"},{"key":"2448_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.12.004","author":"ZS Hasanali","year":"2023","unstructured":"Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, Stadtmauer EA, Cohen AD. Chimeric antigen receptor T cells in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2023. https:\/\/doi.org\/10.1016\/j.hoc.2023.12.004.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"2448_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. 2018;183(3):364\u201374. https:\/\/doi.org\/10.1111\/bjh.15644.","journal-title":"Br J Haematol"},{"issue":"5","key":"2448_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/jcm8050728","volume":"8","author":"T Iba","year":"2019","unstructured":"Iba T, Levy JH, Raj A, Warkentin TE. Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Clin Med. 2019;8(5):728. https:\/\/doi.org\/10.3390\/jcm8050728.","journal-title":"J Clin Med"},{"issue":"1","key":"2448_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12185-020-02992-w","volume":"113","author":"T Ikezoe","year":"2021","unstructured":"Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113(1):34\u201344. https:\/\/doi.org\/10.1007\/s12185-020-02992-w.","journal-title":"Int J Hematol"},{"issue":"7","key":"2448_CR17","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","volume":"98","author":"H Jiang","year":"2019","unstructured":"Jiang H, Liu L, Guo T, Wu Y, Ai L, Deng J, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019;98(7):1721\u201332. https:\/\/doi.org\/10.1007\/s00277-019-03685-z.","journal-title":"Ann Hematol"},{"key":"2448_CR18","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2448_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2448_CR20","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1097\/hs9.0000000000000571","volume":"5","author":"M Levi","year":"2021","unstructured":"Levi M. Pathophysiology of coagulopathy in hematological malignancies and in COVID-19. Hemasphere. 2021;5(6):e571. https:\/\/doi.org\/10.1097\/hs9.0000000000000571.","journal-title":"Hemasphere"},{"issue":"8","key":"2448_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/17474086.2018.1500173","volume":"11","author":"M Levi","year":"2018","unstructured":"Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Rev Hematol. 2018;11(8):663\u201372. https:\/\/doi.org\/10.1080\/17474086.2018.1500173.","journal-title":"Expert Rev Hematol"},{"key":"2448_CR22","doi-asserted-by":"publisher","first-page":"919495","DOI":"10.3389\/fcvm.2022.919495","volume":"9","author":"L Li","year":"2022","unstructured":"Li L, Roest M, Sang Y, Remijn JA, Fijnheer R, Smit K, et al. Patients with multiple myeloma have a disbalanced whole blood thrombin generation profile. Front Cardiovasc Med. 2022;9:919495. https:\/\/doi.org\/10.3389\/fcvm.2022.919495.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"2448_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/hon.3155","volume":"41","author":"R Liu","year":"2023","unstructured":"Liu R, Lv Y, Hong F, Zhao W, Lei B, Liu J, et al. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2. Hematol Oncol. 2023;41(4):704\u201317. https:\/\/doi.org\/10.1002\/hon.3155.","journal-title":"Hematol Oncol"},{"key":"2448_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.thromres.2018.11.022","volume":"173","author":"L Luo","year":"2019","unstructured":"Luo L, Wu Y, Niu T, Han Y, Feng Y, Ding Q, et al. A multicenter, prospective evaluation of the Chinese Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation. Thromb Res. 2019;173:131\u201340. https:\/\/doi.org\/10.1016\/j.thromres.2018.11.022.","journal-title":"Thromb Res"},{"key":"2448_CR25","doi-asserted-by":"publisher","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Z, Ren Z, Li Y. Reactions related to CAR-T cell therapy. Front Immunol. 2021;12:663201. https:\/\/doi.org\/10.3389\/fimmu.2021.663201.","journal-title":"Front Immunol"},{"issue":"2","key":"2448_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11899-017-0373-2","volume":"12","author":"M Ormh\u00f8j","year":"2017","unstructured":"Ormh\u00f8j M, Bedoya F, Frigault MJ, Maus MV. CARs in the lead against multiple myeloma. Curr Hematol Malig Rep. 2017;12(2):119\u201325. https:\/\/doi.org\/10.1007\/s11899-017-0373-2.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"2448_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3. https:\/\/doi.org\/10.3390\/medsci9010003.","journal-title":"Med Sci"},{"issue":"8","key":"2448_CR28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107. https:\/\/doi.org\/10.1002\/ajh.26590.","journal-title":"Am J Hematol"},{"issue":"1","key":"2448_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/hematology.2023000472","volume":"2023","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program. 2023;2023(1):198\u2013208. https:\/\/doi.org\/10.1182\/hematology.2023000472.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2448_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208. https:\/\/doi.org\/10.1016\/j.ctrv.2018.09.001.","journal-title":"Cancer Treat Rev"},{"key":"2448_CR31","doi-asserted-by":"publisher","first-page":"1190379","DOI":"10.3389\/fimmu.2023.1190379","volume":"14","author":"D Shah","year":"2023","unstructured":"Shah D, Soper B, Shopland L. Cytokine release syndrome and cancer immunotherapies\u2014historical challenges and promising futures. Front Immunol. 2023;14:1190379. https:\/\/doi.org\/10.3389\/fimmu.2023.1190379.","journal-title":"Front Immunol"},{"issue":"7","key":"2448_CR32","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41409-021-01226-9","volume":"56","author":"M Shao","year":"2021","unstructured":"Shao M, Yu Q, Teng X, Guo X, Wei G, Xu H, et al. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I\/II clinical trial. Bone Marrow Transplant. 2021;56(7):1642\u201350. https:\/\/doi.org\/10.1038\/s41409-021-01226-9.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2448_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494\u2013502. https:\/\/doi.org\/10.1016\/j.it.2015.06.004.","journal-title":"Trends Immunol"},{"issue":"11","key":"2448_CR34","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7(11):1187\u201399. https:\/\/doi.org\/10.2217\/imt.15.77.","journal-title":"Immunotherapy"},{"issue":"4","key":"2448_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84. https:\/\/doi.org\/10.1038\/s41408-021-00469-5.","journal-title":"Blood Cancer J"},{"issue":"3","key":"2448_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1538-7836.2007.02313.x","volume":"5","author":"CH Toh","year":"2007","unstructured":"Toh CH, Hoots WK. The scoring system of the scientific and standardisation committee on disseminated intravascular coagulation of the international society on thrombosis and haemostasis: a 5-year overview. J Thromb Haemost. 2007;5(3):604\u20136. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02313.x.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2448_CR37","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/s2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361. https:\/\/doi.org\/10.1016\/s2352-3026(21)00057-0.","journal-title":"Lancet Haematol"},{"issue":"4","key":"2448_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.15116","volume":"181","author":"C Varga","year":"2018","unstructured":"Varga C, Laubach JP, Anderson KC, Richardson PG. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018;181(4):433\u201346. https:\/\/doi.org\/10.1111\/bjh.15116.","journal-title":"Br J Haematol"},{"issue":"6","key":"2448_CR39","doi-asserted-by":"publisher","first-page":"e0129170","DOI":"10.1371\/journal.pone.0129170","volume":"10","author":"M Wang","year":"2015","unstructured":"Wang M, Kou H, Deng J, Wang H, Guo T, Mei H, et al. Retrospective evaluation of new Chinese diagnostic scoring system for disseminated intravascular coagulation. PLoS ONE. 2015;10(6):e0129170. https:\/\/doi.org\/10.1371\/journal.pone.0129170.","journal-title":"PLoS ONE"},{"issue":"5","key":"2448_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(5):865\u201375. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.027.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2448_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"2448_CR42","doi-asserted-by":"crossref","unstructured":"Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR-T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024. Accepted for publication.","DOI":"10.1186\/s13045-024-01530-z"},{"issue":"2","key":"2448_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","volume":"343","author":"XJ Xu","year":"2014","unstructured":"Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett. 2014;343(2):172\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2013.10.004.","journal-title":"Cancer Lett"},{"issue":"1","key":"2448_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12964-018-0268-4","volume":"16","author":"MM Zegeye","year":"2018","unstructured":"Zegeye MM, Lindkvist M, F\u00e4lker K, Kumawat AK, Paramel G, Greneg\u00e5rd M, et al. Activation of the JAK\/STAT3 and PI3K\/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal. 2018;16(1):55. https:\/\/doi.org\/10.1186\/s12964-018-0268-4.","journal-title":"Cell Commun Signal"},{"key":"2448_CR45","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153.","journal-title":"Front Immunol"},{"issue":"19","key":"2448_CR46","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.3390\/jcm12196124","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med. 2023;12(19):6124. https:\/\/doi.org\/10.3390\/jcm12196124.","journal-title":"J Clin Med"},{"issue":"1","key":"2448_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141. https:\/\/doi.org\/10.1186\/s13045-018-0681-6.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2448_CR48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86. https:\/\/doi.org\/10.1186\/s13045-022-01301-8.","journal-title":"J Hematol Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02448-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T02:35:26Z","timestamp":1745894126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02448-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2448"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02448-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the Institutional Independent Ethics Committee of the Second Affiliated Hospital of Xi\u2019an Jiaotong University (reference number: 2016002). We confirm that we have obtained the participation informed Consent and publication informed consent from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"ClinicalTrials.gov Identifier: NCT03090659; Registered on March 27, 2017, retrospectively registered.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"631"}}